Aignostics
| Invested since | 2020 |
| Based in | Brandenburg |
About the company
Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary “Explainable AI” platform draws on research from Fraunhofer Society, Charité, and TU Berlin to overcome the typical “black-box” problem of AI in pathology. Aignostics’ focus lies on developing bespoke AI models for clinical trials and CDx development.
Do you want to
know more about this company?
More startups from Life Sciences
Avelios Medical offers a modular software platform for the digitization of workflows in hospitals and data-driven patient care. The state-of-the-art software digitizes and optimizes all workflows in hospitals in a …
To the complete profileof Avelios Medical
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying. The …
To the complete profileof trans.duodenal.concepts
Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach …
To the complete profileof Thermosome
PerformaNat GmbH was founded in 2015 as a spin-off of the veterinary medicine department of the Freie Universität Berlin. The first product – an animal-feed additive for use with dairy …
To the complete profileof PerformaNat
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the …
To the complete profileof TolerogenixX
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
To the complete profileof Lipocalyx